omniture

Yongye Biotechnology International Announces Conference Call to Discuss First Quarter Fiscal Year 2009 Results

Yongye Biotechnology International, Inc.
2009-05-06 19:25 477

BEIJING, May 6 /PRNewswire-Asia-FirstCall/ -- Yongye Biotechnology International, Inc. (OTC Bulletin Board: YGYB) ("Yongye" or the "Company"), a leading distributor of plant and animal nutrient products in the People’s Republic of China, today announced that it will conduct a conference call at 8:00 a.m. Eastern Time on Monday, May 11, 2009 to discuss results for the quarter ended March 31, 2009.

To participate in this live conference call, please dial 888-419-5570 five to ten minutes prior to the scheduled conference call time. International callers should dial 617-896-9871. The conference Passcode is 586 658 26.

For those who are unable to participate in the conference call at the time of the call, a replay will be available for fourteen days starting on May 11, at 10:00 a.m. Eastern Time. To access the replay, please dial 888-286-8010. International callers should dial 617-801-6888. The replay Passcode is 931 813 08.

About Yongye Biotechnology International, Inc.

Yongye Biotechnology International, Inc., headquartered in Beijing, is engaged in the distribution and sales of fulvic acid based nutrients for plants and animals. The Company’s patent pending processes and proprietary formulas allow it to create products that increase crop yields and improve the health of livestock. Its sole operating subsidiary, Yongye Nongfeng Biotechnology Company, Ltd., is located in Inner Mongolia, People’s Republic of China. The Company sells its products through distributors and directly to farmers located in ten provinces throughout China.

Safe Harbor Statement

Certain statements set forth in this press release constitute

"Forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will," "will likely," "should," "could," "would," "may" or words or expressions of similar meaning. All such forward-looking statements involve risks and uncertainties, including, but not limited to: statements regarding the Company’s products; marketing and sales; patents and regulatory approvals; the effect of competition and proprietary rights of third parties; the need for and availability of additional financing and access to capital; the seeking of joint development, licensing or distribution and collaboration and marketing arrangements with other companies. There can be no assurance that such forward-looking statements will prove to be accurate and Yongye undertakes no obligation to update any forward-looking statements or to announce revisions to any of the forward-looking statements.

For more information, please contact:

Yongye Biotechnology International, Inc.

Mr. Larry Gilmore-VP of Corporate Strategy

Tel: +1-818-390-1272

Email: larry.gilmore@gmail.com

CCG Investor Relations, Inc.

Mr. Crocker Coulson, President

Tel: +1-646-213-1915 (New York)

Email: crocker.coulson@ccgir.com

Web: http://www.ccgir.com

Source: Yongye Biotechnology International, Inc.
collection